Skip to content
Peptigraph home

Sermorelin vs CJC-1295: What the Research Shows

Sermorelin and CJC-1295 side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[16]Growth hormoneGHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.[10]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Sermorelin if…

  • you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[16]

Consider CJC-1295 if…

  • you want randomized human hormone data (hormone levels, not a clinical benefit): a single injection raised mean plasma GH 2- to 10-fold for 6 days or more[10]

What they have in common

  • Sermorelin's only FDA record is Geref, listed with marketing status Discontinued[17]
  • WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin[1]
Neither is FDA approved for any use in people. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 5 of 12 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Half-life, Evidence strength are the same or both unknown.

FieldSermorelinCJC-1295
Also called—CJC, mod GRF, GRF 1-29
FDA statusCompounded by prescriptionNot FDA approved · research chemical
Human studies we summarised6 human (1 randomized or controlled) of 9 summarised4 human (1 randomized or controlled) of 7 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 9 mg, 15 mg2 mg, 5 mg, 10 mg

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Sermorelin and CJC-1295 together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 13 results, 2 Oct 2026).

Open the stack page

Short-acting GHRH versus an albumin-binding version

In healthy adults, a single CJC-1295 injection raised mean plasma GH 2- to 10-fold for 6 days or more and IGF-I 1.5- to 3-fold for 9-11 days.[10]

The CJC-1295 trial estimated its half-life at 5.8 to 8.1 days.[10]

After a single CJC-1295 injection in healthy men, the frequency and magnitude of GH pulses were unaltered, while basal (trough) GH levels rose 7.5-fold.[11]

In older men given nightly GHRH (sermorelin's class), treatment did not change weight, BMI, waist-to-hip ratio, DEXA measures of muscle and fat, muscle histology, glucose, insulin or lipids.[6]

Regulatory and safety contrasts

WADA's list names CJC-1295 and sermorelin in the same GHRH-analogue entry, alongside CJC-1293 and tesamorelin.[1]

CJC-1295 has no entry in Drugs@FDA.[20]

FDA's compounding safety page names increased heart rate and systemic vasodilatory reaction as serious adverse events associated with CJC-1295.[21]

In mice, CJC-1295 was less effective when the same dose was given every 48 or 72 hours instead of daily.[12]

Common questions

Is CJC-1295 better than sermorelin?

The CJC-1295 trial estimated a half-life of 5.8 to 8.1 days. This page cites no trial comparing outcomes with sermorelin.[10]

What is the difference between sermorelin and CJC-1295?

CJC-1295 binds permanently to endogenous albumin after injection, and one source gives its half-life as 8 days.[11]

Can you use sermorelin and CJC-1295 together?

No study combining them is cited. WADA's list names both in the same GHRH-analogue entry.[1]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  5. 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  6. 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  7. 7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  11. 11Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  12. 12Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  13. 13PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  17. 17Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  18. 18PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  19. 19PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  20. 20Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  21. 21Official web pageOfficial web page · web page

Found an error? Report a correction.